Joe Willie Smith has always been a creator. As a young child growing up in Milwaukee, his mother encouraged him to make art and find beauty in the everyday. Following years of work in printing and graphic design (including posters for Gil-Scott Heron and Chaka Khan), Smith began channeling his inspiration and creativity into building playable “sonic sculptures” out of found objects. “They’re not all considered instruments…sometimes I just make soundscapes out of them,” Smith says.
As the artist-in-residence for the Promega Fall Art Showcase, Smith set out to create a sonic sculpture from collected items from the Promega campus. He planned to perform on the instrument at the opening of the Art Show, but his creative process led to something much more—a collaborative experience in sound and color.
Community Shares of Wisconsin presented Promega with its Seeds of Change award for our workplace giving efforts. The award is presented to a local business that shows innovation, growth, and commitment to Community Shares of Wisconsin. Over the past 15 years Promega and our employees have collectively contributed more than $717,000 to Community Shares work! Our 100% corporate matching helps employee gifts go twice as far to member nonprofits and the community.
Charitable giving programs and paid time off for community service are examples of Promega’s commitment to corporate responsibility. Learn more at https://www.promega.com/responsibility #corporateresponsibility
Nicole Haselwander and Stephanie Shea were on hand at the Community
Change-Maker Awards hosted by Community Shares of Wisconsin to accept the Seeds
of Change award on behalf of Promega Corporation. “It was an incredibly
inspiring and uplifting program,” says Stephanie.
Promega Corporation today was named one of the “Best Places to Work” in the greater Madison area in Madison Magazine’s annual survey. Promega ranks fifth in the category of large companies with 101+ employees. The “Best Places to Work 2019” list includes 30 local workplaces.
“We are honored to be recognized among these great Madison companies that clearly value their employees and put people first,” says Gayle Paul, Director of Human Resources Operations at Promega. “Nurturing a work environment and culture that allows each person who works at Promega to realize their full potential benefits not only our business and customers, but also each employee, their families and our community as a whole.”
Are you looking for your Best Place to Work? Explore the career opportunities on our website.
The CEDA awards program of the Wisconsin Economic Development Association recognizes businesses, projects and organizations that are making significant contributions to Wisconsin’s economy. Last week Promega won the Business Retention and Expansion award. short.url/aBcXyZ
Standing, walking, running. When was the last time you gave your skeleton a second thought? How about when that car barely missed you in the parking lot? Or a deer ran in front of you? Maybe you just missed a car door opening on your bike ride today?
Your bones were involved in your response to that sudden shock/surprise, but not the way you think.
You may have jumped, swerved or hit the brake pedal (congratulations on the excellent reflexes) and yes, bones were involved in all of those actions. But a new article in Cell Metabolism reveals that bone is the essential component in initiation of that response.
Today’s blog is guest-written by Susanna Harris, a graduate student at the University of North Carolina in Chapel Hill.
thing to hear that everything is going to be okay. It’s another to know it and
make it that way.
At the end
of a lab meeting where I had outlined my last of six years getting my PhD, my
advisor announced she would be moving the lab from North Carolina to Massachusetts
in about six months. Just when everything had settled into place, this
announcement turned my bookshelf of plans on its side once again. Suddenly, I
didn’t know what would happen next.
I chose to
go to grad school partly to challenge myself to accept uncertainty. When I
started my PhD in Microbiology in 2014, I thought this would mean reading new
papers and adjusting experiments accordingly. As it has turned out, the real
challenge has been to constantly get back up as life and graduate school knock
me flat on my ass. Yes, I needed strength to power through, but even more than
that, I needed resilience.
Cardiovascular diseases, or CVDs, are collectively the most notorious gang of cold-blooded killers threatening human lives today. These unforgiving villains, including the likes of coronary heart disease, cerebrovascular disease and pulmonary embolisms, are jointly responsible for more deaths per year than any other source, securing their seat as the number one cause of human mortality on a global scale.
One of the
trademarks of most CVDs is the thickening and stiffening of the arteries, a
condition known as atherosclerosis. Atherosclerosis is characterized by the
accumulation of cholesterol, fats and other substances, which together form
plaques in and on the artery walls. These plaques clog or narrow your arteries
until they completely block the flow of blood, and can no longer supply
sufficient blood to your tissues and organs. Or the plaques can burst, setting
off a disastrous chain reaction that begins with a blood clot, and often ends
with a heart attack or stroke.
Given the global prevalence and magnitude of this problem, there is a significant and urgent demand for better ways to treat CVDs. In a recent study published in Nature Communications, researchers at the Carnegie Institution for Science, Johns Hopkins University and Mayo Clinic are taking the fight to CVDs through the study of low-density lipoproteins (LDLs), the particles responsible for shuttling bad cholesterol throughout the bloodstream.
Here in Technical Services we often talk with researchers at the beginning of their project about how to carefully design and get started with their experiments. It is exciting when you have selected the Luciferase Reporter Vector(s) that will best suit your needs; you are going to make luminescent cells! But, how do you pick the best way to get the vector into your cells to express the reporter? What transfection reagent/method will work best for your cell type and experiment? Do you want to do transient (short-term) transfections, or are you going to establish a stable cell line?
In recent years, it’s become a well-documented fact that koalas are about as picky as they are adorable. These beloved Australian marsupials have evolved to become ecological specialists: consumers that feed primarily on a single organism, or small number of organisms. Eucalyptus, their organism of choice, encompasses approximately 900 species, most of which are native to Australia. To the koala’s benefit, the leaves of eucalyptus trees are difficult to digest, low in protein content and their chemical composition contains compounds that are toxic. This makes their competition for eucalyptus with other species virtually nonexistent.
That’s not to say there isn’t competition amongst themselves. Of those 900 species of eucalyptus, koalas are only really known to feed on about 40–50 of them, and of those 40–50, they tend to limit their diet to around 10. Depending on their location, however, some koalas will only stick to one preferred type, which can lead to trouble.
In the late-80’s through the 90’s, food and health agencies focused
on a mysterious fatal brain disease that infected thousands of cattle. Bovine
spongiform encephalitis—or “mad cow disease”—is caused by an infectious protein
called a prion. Despite fears that tainted meat would cause the disease to
spread to humans, mad cow disease never really made an impact on human health.
However, forms of the prion disease such as Creutzfeldt-Jakob disease do affect
In addition to Creutzfeldt-Jakob disease, many neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) are now thought to be a result of prion-like activity. There is no cure for these diseases, however, new experimental treatment strategies might help slow the progression of neural degeneration.